Skip to main content

Advertisement

Table 1 Clinicopathological characteristics and prognostic factors of 161 patients with OSCC measured by negative and positive Apo10 and TKTL1 expressors

From: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells

Characteristics Number of patients p-value Number of patients p-value
  Total Apo10 expression Apo10 expression   TKTL1 expression TKTL1 expression  
negative (<10%) positive (≥10%) negative (<10%) positive (≥10%)
n = 161 n = 29 (18%) n = 132 (82%) n = 93 (58%) n = 68 (42%)
Age (y)     0.5445    0.7507
<60 ± 11.8 80 (49.7%) 16 (20%) 64 (80%)   45 (56%) 35 (44%)  
≥60 ± 11.8 81 (50.3%) 13 (16%) 68 (84%)   48 (59%) 33 (41%)  
Gender     0.8016    0.4501
Male 122 (75.8%) 23 (19%) 99 (81%)   73 (60%) 49 (40%)  
Female 39 (24.2%) 6 (15%) 33 (85%)   20 (51%) 19 (49%)  
Site distribution of OSCC     0.8991    0.8782
Lips 11 (6.8%) 3 (27%) 8 (73%)   9 (82%) 2 (18%)  
Tongue 41 (25.5%) 8 (20%) 33 (80%)   21 (51%) 20 (49%)  
Floor of the mouth 64 (39.8%) 10 (16%) 54 (84%)   37 (58%) 27 (42%)  
Palate 15 (9.3%) 0 (0%) 15 (100%)   6 (40%) 9 (60%)  
Buccal mucosa 8 (5.0%) 3 (38%) 5 (62%)   6 (75%) 2 (15%)  
Alveolar ridge 22 (13.7%) 5 (23%) 17 (77%)   14 (64%) 8 (36%)  
Histological Grading     0.4765*    0.7396*
G1 41 (25.5%) 10 (24%) 31 (76%)   23 (56%) 18 (44%)  
G2 106 (65.8%) 15 (14%) 91 (86%)   63 (59%) 43 (41%)  
G3 13 (8.1%) 3 (23%) 10 (77%)   6 (46%) 7 (54%)  
G4 1 (0.6%) 1 (100%) 0 (0%)   1 (100%) 0 (0%)  
Tumor size     0.0194**    0.0018**
pT1 64 (39.8%) 14 (22%) 50 (78%)   46 (72%) 18 (28%)  
pT2 42 (26.1%) 11 (26%) 31 (74%)   25 (59%) 17 (41%)  
pT3 17 (10.6%) 0 (0%) 17 (100%)   5 (29%) 12 (71%)  
pT4 38 (23.6%) 4 (11%) 34 (89%)   17 (45%) 21 (55%)  
Cervical lymph node metastasis     0.5638    0.0008
pN0 118 (73.3%) 23 (19%) 95 (81%)   78 (66%) 40 (34%)  
pN1-3 43 (26.7%) 6 (14%) 37 (86%)   15 (35%) 28 (65%)  
UICC stage     0.0025***    <0.0001***
UICC I 48 (29.8%) 12 (25%) 36 (75%)   42 (88%) 6 (12%)  
UICC II 36 (22.4%) 11 (31%) 25 (69%)   23 (64%) 13 (36%)  
UICC III 31 (19.3%) 1 (3%) 30 (97%)   11 (35%) 20 (65%)  
UICC IV 46 (28.6%) 5 (11%) 41 (89%)   17 (37%) 29 (63%)  
Locoregional recurrence     0.0125    <0.0001
No 117 (72.7%) 27 (23%) 90 (77%)   81 (69%) 36 (31%)  
Yes 44 (27.3%) 2 (5%) 42 (95%)   12 (27%) 32 (73%)  
Extracapsular spreading of lymph nodes     0.0452    0.0099
No 143 (88,8%) 29 (20%) 114 (80%)   88 (62%) 55 (38%)  
Yes 18 (11,2%) 0 (0%) 18 (100%)   5 (28%) 13 (72%)  
Adjuvant therapy (RTx, Ctx)     0.1202    0.6337
No 111 (68,9%) 24 (22%) 87 (78%)   66 (59%) 45 (41%)  
Yes 50 (31,1%) 5 (5%) 45 (95%)   27 (54%) 23 (46%)  
  1. Abbrevations: y years, G grading, UICC International Union against Cancer, *G1/2 vs. G3/4, **pT1/2 vs. pT3/4, ***UICC I/II vs. UICC III/IV, RTx radiotherapy, CTx chemotherapy.